Can Fite Biopharma Ltd
CANF4.160USD
+0.100+2.35%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
5.50MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Can Fite Biopharma Ltd Unternehmen
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Can Fite Biopharma Ltd Informationen
BörsenkürzelCANF
Name des UnternehmensCan Fite Biopharma Ltd
IPO-datumSep 22, 2005
CEOFishman (Pnina)
Anzahl der mitarbeiter5
WertpapierartDepository Receipt
GeschäftsjahresendeSep 22
Addresse10 Bareket Street, Kiryat Matalon
StadtPETAH TIKVA
BörseNASDAQ OMX – NASDAQ Basic Amex
LandIsrael
Postleitzahl49170
Telefon97239241114
Websitehttps://www.canfite.com/
BörsenkürzelCANF
IPO-datumSep 22, 2005
CEOFishman (Pnina)
Führungskräfte von Can Fite Biopharma Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Sari Fishman, Ph.D.
Dr. Sari Fishman, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Yoseph Borenstein
Mr. Yoseph Borenstein
Director
Director
--
--
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Sari Fishman, Ph.D.
Dr. Sari Fishman, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Tue, Jan 6
Aktualisiert: Tue, Jan 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Sabby Management, LLC
5.37%
Rhumbline Advisers Ltd. Partnership
0.22%
Abalone Asset Management Ltd.
0.09%
UBS Financial Services, Inc.
0.08%
BNP Paribas Securities Corp. North America
0.06%
Andere
94.17%
Aktionäre
Aktionäre
Anteil
Sabby Management, LLC
5.37%
Rhumbline Advisers Ltd. Partnership
0.22%
Abalone Asset Management Ltd.
0.09%
UBS Financial Services, Inc.
0.08%
BNP Paribas Securities Corp. North America
0.06%
Andere
94.17%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
5.37%
Investment Advisor
0.51%
Research Firm
0.12%
Hedge Fund
0.04%
Andere
93.96%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
30
1.56M
6.39%
--
2025Q3
33
1.56M
9.88%
+633.60K
2025Q2
31
928.79K
6.69%
+773.65K
2025Q1
30
155.14K
8.36%
-710.63K
2024Q4
28
138.24K
8.71%
-639.91K
2024Q3
26
778.14K
10.55%
+126.51K
2024Q2
26
651.74K
10.05%
+134.05K
2024Q1
24
517.69K
5.29%
+253.94K
2023Q4
29
283.94K
2.08%
+216.17K
2023Q3
28
67.77K
12.19%
+13.03K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Sabby Management, LLC
70.30K
5.37%
+31.32K
+80.32%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
2.90K
0.22%
+18.00
+0.63%
Sep 30, 2025
Abalone Asset Management Ltd.
1.19K
0.09%
-809.00
-40.45%
Jun 30, 2024
UBS Financial Services, Inc.
65.00
0.01%
-211.00
-76.45%
Sep 30, 2025
BNP Paribas Securities Corp. North America
829.00
0.06%
-50.00
-5.69%
Sep 30, 2025
Bogart Wealth, LLC
752.00
0.06%
+752.00
--
Sep 30, 2025
Morgan Stanley & Co. LLC
626.00
0.05%
+130.00
+26.21%
Sep 30, 2025
CAPTRUST Financial Advisors
569.00
0.04%
--
--
Sep 30, 2025
Two Sigma Investments, LP
532.00
0.04%
-271.00
-33.75%
Sep 30, 2025
MainStreet Advisors
150.00
0.01%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 23, 2025
Merger
20→1
Dec 23, 2025
Merger
20→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 23, 2025
Merger
20→1
Dec 23, 2025
Merger
20→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
